提高儿科脊柱融合预先认证的效率
Lynessa McGee1, Jen Anadio1, Taryn McCarthy-Isfort1
1Division of Orthopaedic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Journal of the Pediatric Orthopaedic Society of North America
|February 2, 2026
概括
实施标准化手术前模板和在手术前至少4周安排访问,显著减少了儿科脊柱融合的预证拒绝. 这项质量改善计划使拒绝率从15.4%降至2.9%,从而减轻了行政负担.
科学领域:
- 提高医疗保健的质量 改善医疗保健的质量
- 医疗保健服务研究 医疗服务研究
- 手术操作管理手术操作管理
背景情况:
- 保险公司的预先认证流程旨在制不必要的支出,但可能导致严重的行政负担.
- 儿科脊柱中心在2022年经历了更多的拒绝和对等互动,以获得预先认证.
- 启动了一项质量改进项目,以减轻与预先认证上诉相关的时间和资源需求.
研究的目的:
- 为了减少预先认证拒绝和儿科脊椎中心同行互动的行政负担.
- 识别和解决脊髓融合否认的主要原因.
- 提高儿科脊柱手术预认证流程的效率.
主要方法:
- 进行了帕雷托分析,以确定脊髓融合拒绝的主要原因.
- 干预措施是使用关键驱动器图表开发的,并通过计划-做-研究-行动循环来实施.
- 关键干预措施包括标准化手术前模板和将手术前访问转移到手术前至少4周.
主要成果:
- 帕雷托分析确定"支持性文件"和"医疗上不必要"是拒绝的首要原因.
- 实施手术前模板 (2023年3月) 和调整访问时间 (2023年5月) 导致拒绝显著减少.
- 月均拒绝率从2023年5月之前的15.4%下降到实施后的2.9%.
结论:
- 质量改进方法,特别是标准化模板和早期的手术前访问,有效地减少了儿科脊柱融合的预证拒绝.
- 解决关键拒绝原因简化了预先认证过程,减少了外科医生同行互动的需要.
- 这些效率改进可以帮助减轻行政义务,并可能减少医生倦怠.
相关概念视频
Nuclear Fusion
33.9K
The process of converting very light nuclei into heavier nuclei is also accompanied by the conversion of mass into large amounts of energy, a process called fusion. The principal source of energy in the sun is a net fusion reaction in which four hydrogen nuclei fuse and ultimately produce one helium nucleus and two positrons.
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
33.9K
Tagging and Fusion Proteins
8.5K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.5K
SNAREs and Membrane Fusion
12.7K
Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
12.7K
Pharmacokinetics in Pediatric Patients: Drug Excretion
262
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
262
Pharmacokinetics in Pediatric Patients: Drug Distribution
304
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
304
Pharmacokinetics in Pediatric Patients: Drug Metabolism
226
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
226


